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Remote monitoring (RM) of homebound heart failure (HF) patients has previously been shown to reduce hospital admissions.
We conducted a pilot trial of ambulatory, non-homebound patients recently hospitalized for HF to determine whether RM could
be successfully implemented in the ambulatory setting. Eligible patients from Massachusetts General Hospital (n = 150) were
randomized to a control group (n = 68) or to a group that was oﬀered RM (n = 82). The participants transmitted vital signs
data to a nurse who coordinated care with the physician over the course of the 6-month study. Participants in the RM program
had a lower all-cause per person readmission rate (mean = 0.64, SD ± 0.87) compared to the usual care group (mean = 0.73,
SD ± 1.51; P-value = .75) although the diﬀerence was not statistically signiﬁcant. HF-related readmission rate was similarly
reduced in participants. This pilot study demonstrates that RM can be successfully implemented in non-homebound HF patients
and may reduce readmission rates.
1.Introduction
Heart failure aﬀects over 5 million people in the US, and its
incidence and prevalence are rising rapidly, despite advances
inHeartFailure(HF)therapies.HospitalizationsforHFhave
nearly tripled in the last three decades, and it is now the
most common cause of hospitalization in the US among the
elderly [1, 2]. In addition to the substantial morbidity and
mortality, the costs associated with HF care (in particular
HF hospitalizations) are $37.2 billion [3, 4]. Therefore, novel
approaches are essential to reduce the morbidity and costs
associated with HF hospitalizations.
Although two decades of research underscores the
importance of evidence-based pharmacologic management
ofHFpatients,itisnowappreciatedthatnon-pharmacologic
interventions can also signiﬁcantly inﬂuence HF outcomes
[5]. A growing body of evidence suggests that non-
pharmacological interventions implemented by multidis-
ciplinary teams across the inpatient and outpatient con-
tinuum can reduce hospitalizations and/or deaths in HF
patients [6, 7]. An innovative care delivery model that has
recently shown promise is the use of remote monitoring
(RM) technology. Remote monitoring programs acquire and
securely transmit data on patients’ HF signs and symptoms
to health care teams, alert providers to the early signs of
clinical deterioration, and create opportunities for timely
intervention. RM also involves patients in their own care and
allows them to link behaviors and their consequences (e.g.,
nonadherence to medications and subsequent weight gain)
[8, 9].
Recent meta-analysis has concluded that RM programs
forHFpatientsreducehospitaladmissionsandmortalityand2 International Journal of Telemedicine and Applications
simultaneously improve health related quality of life [10–
12].PriorstudieshavedemonstratedthatRMofhomebound
HF patients signiﬁcantly reduced home visits by trained
nurses and reduced hospital readmissions [13, 14]. It is
not known, however, whether the beneﬁts of RM extend to
ambulatory, non-homebound HF patients. The objective of
this pilot study was (1) to determine whether RM could be
successfully implemented in non-homebound HF patients,
(2) to assess satisfaction with RM among ambulatory HF
patients, and (3) to obtain preliminary estimates of the 6-
month hospital readmission rate between non-homebound
patients who participated in an RM program and patients
who either declined (non-participants) or were not oﬀered
the opportunity to participate (control).
2. Methods
2.1. Study Design. A daily chart review of patients hospi-
talized with HF at Massachusetts General Hospital (MGH)
was conducted between July 2006 and June 2007. Eligibility
criteria for study participation included all of the following:
current admission or recent discharge (within prior 2 weeks)
from MGH with a primary diagnosis of HF, considered high
risk for readmission (history of hospital readmissions for
cardiac-related reasons or ejection fraction ≤20%), non-
homebound, age over 18 years, not awaiting cardiac or
renal transplant, English speaking, mentally competent (or
willing primary caregiver), a working telephone line with a
3 prong electric outlet, and a Partners-aﬃliated physician
or cardiologist (Partners HealthCare is an integrated health
care system founded by Brigham and Women’s Hospital and
Massachusetts General Hospital in Boston). Eligible patients
were prospectively randomized on a week-on and week-oﬀ
basis either to a group that was oﬀered RM or to a control
group that was not oﬀered RM; that is, participants were
allocated to a diﬀerent group each week (Figure 1). Physician
agreement was also required. Patients who were oﬀered RM
but who refused RM or for whom physician approval could
not be obtained were analyzed as a separate arm of the
study (non-participants). RM participants received home
monitoring for six months after hospital discharge and the
controlandnon-participantgroupreceivedstandardcarefor
a similar time period. All patients were followed for a period
of six months from the time they were identiﬁed. The study
was approved by Partners Institution Review Committee.
The program was oﬀered free of charge to eligible patients
regardless of insurance status.
2.2. Remote Monitoring Intervention. For patients who
agreed to be in the RM arm, there were two nursing
visits to obtain consent, assess patient baseline parameters,
and establish competency with technology. Physician orders
were obtained before the nurse arranged a home visit.
During the ﬁrst visit, the visiting nurse obtained informed
consent and instructed the patient and family about using
the RM equipment. The second visit occurred within one
week to make sure that the patient was comfortable using
the technology and understood the procedures. Enrolled
patients were taught how to measure their vital signs and
weight, and transmit the readings to the RM nurse (a
registerednursepractitionerwithexperienceinmanagement
of cardiac patients). The RM nurse made weekly phone calls
to the patients to provide additional instruction as needed,
monitor adherence to the RM program, and solicit patient
feedback about the program. Patients were instructed to
transmit monitor readings including weight, blood pressure,
pulse, and pulse oximetry on a daily basis. The Remote
monitoring equipment included VitelNet, FDA-approved
devices: a UA 767PC Turtle 400 monitor monitoring, a Life-
Sourcedigitalweightscale,anA&Dbloodpressure/pulsecuﬀ
and meter, and a BCI pulse oximeter device (UC-321PBT).
Patient data were transferred securely via telephone service
to the Internet. They also answered a set of symptom-
related questions including changes in shortness of breath or
swelling.
Vital ranges were established for each patient in con-
sultation with their physician. If the readings received were
outside the range expected for the patient, the RM nurse
telephoned the patient to discuss the results. Increase in
body weight was particularly emphasized as it is a strong
predictor of hospitalization [15, 16]. The skilled nursing
portion of the telephone call included evaluation of the
RM readings and a telephone assessment of the patient.
The RM nurse further evaluated patients who experienced
clinical signs or symptoms of a worsening condition. Nurse
recommendations included increased diuretic dose (if a
physician’s order was in place), physician or cardiologist
notiﬁcation, referral to the ER, and continued monitoring.
To assess the patients’ perceptions of the RM experience,
patients were mailed surveys to complete at the end of the
6 month intervention. Questions for the satisfaction surveys
were taken from previously validated surveys [17, 18]. New
questions were added about technology perception ease of
equipment use, program satisfaction, and option for open
comments from patients. The ﬁnal survey tool was tested
during the study design phase but was not validated or
checked for reliability.
2.3. Data Collection. Data on baseline information, previous
and new readmissions, and other outcomes were collected
through chart reviews by a physician. Any uncertainty
regarding cause of readmissions was referred to an inde-
pendent physician for arbitration. In addition to hospi-
tal records, we ascertained six-month mortality on study
patients through the Social Security Death Index [19].
2.4. Statistical Analysis. The primary outcome for the study
was all-cause re-hospitalization rate, determined by dividing
total number of readmissions by the number of patients in
eachgroup.Secondaryendpointsincludedre-hospitalization
rate for HF, mortality, ER visits, length of stay, and partic-
ipant satisfaction. We treated readmission rates as a con-
tinuous measure because patients with HF often experience
multiple hospitalizations over a six-month period. Average
length of stay was calculated by dividing the total number of
inpatient days by the number of admissions in each group.International Journal of Telemedicine and Applications 3
Primary outcomes: all cause re-hospitalization rate.
Secondary outcomes: HF-re-hospitalization rate, ER visits, mortality, length of stay and subject satisfaction.
Primary analysis: comparison of outcomes in groups (A) versus (B) versus (C).
Secondary analysis (intention-to-treat): comparison of group (A) versus groups (B) and (C) together.
RM participants
(n = 42)
RM non-participants
(n = 40)
24 patient refusals
16 physician refusals
Week oﬀ:c o n t r o l
(n = 68)
(A)
(B) (C)
Week on: oﬀered
intervention (n = 82)
Eligible patients (n = 150)
Screened patients (n = 1786)
Patients ineligible for the study (n = 1636)
Died = 4D i e d = 4D i e d = 3
Figure 1: Study ﬂow diagram. RM: Remote Monitoring; HF: Heart Failure; ER: Emergency Room visits.
All rates were compared between the three arms of the study:
control, participant, and the non-participant group during
aninterimanalysisatthree-monthstageandattheendofthe
six months. Diﬀerences in primary and secondary outcomes
betweenthecontrolandRMgroupwerealsocomparedusing
intention-to-treat analysis in which all patients oﬀered RM,
whether or not they agreed to RM, were analyzed together
(Figure 1). Baseline variables and outcomes were compared
between the groups using ANOVA for continuous variables
and Fischer exact test for categorical variables. The Wilcoxon
rank sum test was used for estimating readmission rates,
ER visits, and Length of stay. All analyses were performed
using SAS (SAS V.9 Cary, North Carolina) statistical software
package.
3. Results
A total of 150 eligible subjects were identiﬁed over the course
of one year and randomly assigned to control (n = 68,
mean age = 70 ± 1.7y e a r s )o rR Mg r o u p( n = 82, mean
age = 66 ± 2.2 years). Of the 82 patients who were oﬀered
RM, 40 patients did not participate (patient refused = 24,
physician refused = 16). Patients most commonly declined
to participate because they were too busy, unsure of the
technology, or worried that monitoring would make them
feel disabled. Physicians who refused on behalf of their
patients most frequently cited dislike of technology, fear of
information overload, and doubt that their patient would
cooperate.
A summary of participant baseline characteristics and
comorbidconditionsbystudyarmisincludedinTable 1.The
study sample had 44% females and it was a predominantly
white population, above the age of 65 years. A majority
of the patients were on Medicare, Medicaid, or other state
insurance (77%). The three study arms were comparable
for common comorbid conditions, cardiac medications, and
ejection fraction. Excluding the index admission, patients
had on an average less than one admission or ER visit due
to HF in the previous year.
Within 30 days of index admission, there were seven
readmissions in control group, four readmissions in the RM
intervention, and six readmissions in the non-participants.
Participants in the RM program had a lower mean all-
cause readmission rate (mean = 0.64, SD ± 0.87) compared
with control (mean = 0.73, SD ± 1.51) and non-participant
(mean = 0.75, SD ± 1.05) groups although this did not
reach statistical signiﬁcance (P-value = .75). The rate of
HF-related readmissions was also similarly lower in the RM
group (mean = 0.19, SD ± 0.45) compared to the control4 International Journal of Telemedicine and Applications
Table 1: Baseline characteristics and last one-year admissions.
Characteristics Control
(n = 68)
Intervention
participants
(n = 42)
Intervention
non-participants
(n = 40)
P-value∗
Male gender (%) 64.7 61.9 45 .13
W h i t er a c e( % ) 90 83.5 87.5 .64
Age, y, (mean ± SD) 70.2 (±1.7) 65.0 (±2.2) 67.9 (±2.3) .2
Depression (%) 17.6 11.9 17.5 .71
Hypertension (%) 73.5 64.3 70 .58
Diabetes (%) 48.5 40.5 55 .42
Creatinine mg/dl (mean ± SD) 1.54 (±0.77) 1.51 (±0.86) 1.58 (±0.87) .92
Ejection Fr. (mean ± SD) 0.37 (±0.18) 0.39 (±0.23) 0.42 (±0.21) .51
No. of Cardiac meds† 6.2 (±0.24) 6.1 (±0.31) 5.7 (±0.32) .41
Total no. of meds 11.6 (±0.55) 11.5 (±1.04) 10.8 (±0.21) .64
Readmissions per patient in last 12months prior to index hospitalization (mean ± SD)
All cause 1.17 (±0.17) 0.75 (±0.22) 1.0 (±0.23) .34
HF-related 0.8 (±1.04) 0.7 (±1.04) 0.6 (±0.69) .78
ER visits (mean ± SD)
All cause 1.34 (±1.47) 1.26 (±1.99) 1.65 (±1.83) .16
HF-related 0.5 (±0.76) 0.57 (±1.34) 0.9 (±0.90) .007
∗(P-value = .05). †Cardiac medications included Anticoagulants, vasodilators, digitalis, statins, diuretics, antiplatelet agents, angiotensin II receptor blockers,
ACE-Inhibitors, Beta blockers, and calcium channel blocker.
group (mean = 0.38, SD ± 1.06; P = .56) (Table 2). Interim
analysis at the end of three-month stage had shown similar
trends. Inpatient length of stay was shorter for the RM
group as compared to non-participant and control groups
(Table 2). All-cause ER visits, however, were higher in the
RM group (0.83, SD ± 1.08) compared to the control group
(0.57, SD ± 1.43; P-value = .10) which may be the result
of patients more frequently reporting to the ER because
of closer monitoring. An intention-to-treat analysis did not
alter the results or the trends seen in the main analyses
(Table 3).
A total of 11 patients (four patients in control; four in
RM; three in non-participants) died during the six-month
period. Additionally, four patients in the RM group did not
complete the full length of the program. Of the four, two
patients moved to another city and were then not cared for
by a Partners physician, and two stopped sending readings
despite repeat phone calls from the RM nurse. For these
subjects, all events up until the time of censoring were
accounted for in the main analysis. The overall trends were
not aﬀected when the analysis was repeated leaving out
subjects who died or did not complete the program.
On completion of the program, 20 of 42 subjects in
the RM arm returned the satisfaction survey (response rate
48%). All these participants reported high level of satisfac-
tion, with 93% respondents agreeing that the equipment
was easy to use; the program improved their HF control;
the program helped them stay out of hospital. All (100%)
respondents reported that the equipment was simple and
easy to use and the program made them feel more in control
of their health. The majority of respondents (80%) also
believed that the program should continue longer and was
further supported by open comments such as “excellent
opportunity to become more aware of my disease condition”
and “with the program I have a tendency to be diligent about
my diet and weight.”
4. Discussion
This pilot study demonstrated a trend towards a lower all-
cause readmission rate in the RM group (0.64) doing better
than the control (0.73), who in turn did better than the non-
participant (0.75) groups. RM participants also had lower
HF-related readmissions compared with the control group.
We observed high level of patient satisfaction (93%) among
RM participants and barriers to uptake of this technology
were identiﬁed among non-participants. Thus our study
demonstrates that not only can RM be successfully employed
to deliver followup care, but also extending its use to a larger
population may be potentially of great value to both patients
and providers.
As this is a pilot study that was not powered to demon-
strate signiﬁcant diﬀerences between groups in important
HF-related endpoints, it is not surprising that the rates
of these endpoints that we observed were not statistically
diﬀerent. The successful implementation of the RM pro-
gram, the high degree of patient satisfaction, and the trends
do suggest that RM may reduce HF hospitalizations and
this certainly warrants further study. Our RM program was
designed to prevent HF-related readmissions and it may
have had less impact on all-cause readmissions (our primary
outcome) for diverse reasons in the short period of study.
There is also high comorbidity in HF patients. The event
rate we observed in ambulatory patients is also much lowerInternational Journal of Telemedicine and Applications 5
Table 2: Six-month followup readmission rates and ER visit rate.
Hosp. readmissions (mean ± SD) Control (n = 68)
Intervention
Participants
(n = 42)
Intervention
non-participants
(n = 40)
P-value∗
All cause 0.73 (±1.51) 0.64 (±0.87) 0.75 (±1.05) .75
HF-related 0.38 (±1.06) 0.19 (±0.45) 0.42 (±0.93) .56
ER visits (mean ± SD)
All cause 0.57 (±1.43) 0.83 (±1.08) 0.65 (±1.0) .1
HF-related 0.25 (±1.02) 0.26 (±0.49) 0.35 (0.80) .31
Length of stay (mean ± SD)
All cause 10.64 (±9.7) 9.16 (±9.00) 13.2 (±13.4) .85
HF-related 8.52 (±8.3) 10.57 (±12.5) 10.78 (±9.1) .78
∗(P-value = .05).
Table 3: Six-month results by Intention to Treat.
Hosp.
readmissions
(mean ± SD)
Control
(n = 68)
Intervention†
(n = 40)
P-value∗
All cause 0.73 (±1.51) 0.69 (±0.96) .46
HF-related 0.38 (±1.06) 0.30 (±0.73) .5
ER visits
(mean ± SD)
All cause 0.57 (±1.43) 0.74 (±1.04) .06
HF-related 0.25 (±1.02) 0.30 (±0.66) .12
Length of stay
(mean ± SD)
All cause 10.64 (±9.7) 11 (±11.34) .96
HF-related 8.52 (±8.3) 10.68 (±10.36) .55
∗(P-value = .05). †Intervention includes all patients who were oﬀered the
opportunity to participate.
than that of homebound patients as demonstrated by the
fact that patients in our pilot had on an average less than
one HF-related readmission and ER visit in the year prior
to index hospitalization (see Table 1). As such, the pilot’s
moderate sample size and short duration of followup (6
months) may have not allowed capture of suﬃcient events
for trends to reach statistical signiﬁcance. However, this pilot
study indicates the value of studying the use of RM in a
larger ambulatory population. Large-scale randomized trials
are currently underway to elucidate the role of RM in HF
management [20].
National eﬀorts to disseminate RM approaches are
growing. The Department of Veterans Aﬀairs and various
managed care organizations now use RM to care for patients
with a variety of chronic conditions. A Veterans Aﬀairs study
demonstrated that the total number of inpatient hospital
days for HF patients receiving RM fell from 630 for the
previous year to 122 over the duration of the program
[21]. The Centers for Medicare & Medicaid Services (CMS),
an agency of the U.S. Department of Health and Human
Services, is targeting readmissions to the hospital within 30
days of discharge as a probable marker for poor quality
and eﬃciency of care [22]. Medicare has indicated that they
may change payment policies that would result in hospitals
with high risk-adjusted rates of readmissions receiving lower
average per case payments than they do now. The specter of
reimbursement cuts has stimulated some healthcare systems
to invest in strategies to lower readmission rates. Remote
monitoring has been identiﬁed as one of the potential
intervention that can reduce avoidable readmissions. Our
study provides evidence that the beneﬁt of RM can be
extended to the larger population of non-homebound
patients traditionally excluded from such interventions.
Our ﬁndings also support previous studies that have
shown beneﬁts from RM, although the extent and nature
of eﬀects has varied across diﬀerent outcomes [23–32].
Our study contributes to the literature by demonstrating
the beneﬁt of RM to ambulatory patients traditionally
excluded from such programs. It was designed to addi-
tionally show feasibility, identify barriers to RM uptake
in non-homebound patients, ascertain patient satisfaction,
and provide data on event rates to guide future, larger
trials. Our pilot trial has some important limitations. The
study has a small sample size and was not powered to
evaluate for diﬀerences in important clinical endpoints. We
cannot ascertain which aspects of the RM program (weekly
telephone calls, regular transmission of data, education, etc.)
leadtotheobservedbeneﬁts.Inaddition,someaspectsofthe
servicemaybetime-consumingtodeliverbutaddlittletothe
eﬀectiveness of the program. There are currently no standard
methods forevaluating suchprograms, or agreementaround
standard deﬁnitions. This makes it diﬃcult to decisively
measure the impact of technology on delivery of care.
Although we prospectively captured all hospitalizations and
mortality events in a rigorous and complete manner, cost
data and out-patient visit data were not fully ascertained.
Cost analysis would be important especially if RM increases
ER visits as happened in our study. Our qualitative surveys,
although very positive, had modest completion rates (48%).
The survey questions have been taken from prior studies but
were not validated and were collected only at the end of the
6 months. Hence they may not accurately reﬂect change in
perceptions or quality of life over a longer-term period.
Despite these limitations, the results from our pilot are
suﬃciently encouraging to warrant a larger randomized trial6 International Journal of Telemedicine and Applications
of RM technology within an ambulatory patient population.
Our program found strong support from patients and
their physicians who participated in the intervention and
expressed their interest in continuing the program. We are
currently oﬀering a modiﬁed version of this program across
all Partners hospitals in the Greater Boston area; to date over
300 patients have participated. Our modiﬁcations are based
on the feedback received from participating patients and
physicians, and we have addressed several barriers that were
identiﬁed in the pilot trial. Current improvements include
the development of a shared portal that allows more eﬃcient
communication between the RM nurse and the patient’s care
team, increased use of orders that allow the RM nurse to
make timely treatment changes that have been approved by
thepatient’sphysician,identiﬁcationofphysicianchampions
whopromotetheprogramamongsttheircolleagues,creation
of a patient video to help prospective patients understand
what the program involves and hear positive reactions from
past participants, and use of an opt-out system where
patients are enrolled unless a physician expressly declines
thus increasing the proportion of eligible patients who get
enrolled. We believe that these measures will enhance both
the uptake and eﬀectiveness of the overall program.
In our pilot, 48% of the patients oﬀered RM did not
participate because either they or their physician refused.
Implementation of the changes described above has lowered
the refusal rate to 10%. The non-participant group remains
of considerable interest to us because in our pilot they had
the worst outcomes in terms of readmissions and ER visits.
Ongoing eﬀorts need to be made to overcome barriers to
adoption in order that these patients can realize the beneﬁts
of RM. Although technology costs have fallen considerably
over time, RM programs are likely to remain a limited
resource and its use should be prioritized in candidates
at highest risk for HF rehospitalizations. Adoption of a
standardized methodology and framework for evaluation of
these programs would be important for comparing diﬀerent
RM programs and identifying key features that promote
success and the patient segments most likely to beneﬁt.
In conclusion, our pilot trial has demonstrated that the
use of RM is a promising approach that has potential to
reduce morbidity and increase patient satisfaction in non-
homebound HF patients. Further investigation is warranted
to determine how RM can be eﬀectively implemented to
optimize HF outcomes.
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